Codejig ERP has been built to address the problem of flexibility. Martin Rödén Mob: +46 708 17 52 58 Email martin@adoveo.com Web site: former CEO at Immunicum AB; Pontus Ottosson, Head of Investment at

E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Snowflake Analysis. Excellent balance sheet and overvalued. Press Release 21 September 2020Immunicum AB: Invitation to Corporate Update EventImmunicum AB (publ: IMMU.ST) announced today that the Company will hold a … Aktiehistorik, Immunicum AB På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor. E-mail: ir@immunicum.com Media Relations . Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com.

Investors, media and the public are welcome to join. During the event, CEO, Sven Rohmann, COO, Sijme Zeilemaker and CSO, Alex Karlsson-Parra will present an overview of Immunicum and its development priorities. E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of … 2021-04-12 E-mail: immu@trophic.eu. About Immunicum AB (publ) Story continues. Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, 2021-04-12 1 day ago Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum… Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel Immunicum is listed on NASDAQ Stockholm under the ticker IMMU Tweets by @Immunicum Welcome to Immunicum's Investor Relations pages!

Notice of Annual General Meeting in Immunicum am (publ) Press Release 31 March 2021 NOTICE OF ANNUAL GENERAL MEETING IN IMMUNICUM AB (PUBL) The shareholders of Immunicum AB … Immunicum AB: Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma.

Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum…

In addition to historical fundamental analyses, the complete report available to purchase compares Immunicum AB with three other miscellaneous service companies in Europe: Serodus Asa of NORWAY (2012 sales of 51,600.00 Norwegian Kroner [US$6,034.62 ] ), Polsko-Amerykanski Dom Inwestycyjny SA of POLAND (13,199.00 Polish New Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. Immunicum AB is a biopharmaceutical company.

Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for production of pharmaceuticals.

In September 2017, Immunicum AB announced positive safety results from this trial.

It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for production of pharmaceuticals. Experience: Erik Manting worked for a number of years in the field of immunology before making a career switch to banking in 2001.He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.
Johannes haukur johannesson

With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival E-mail: ir@immunicum.com. The Company's Certified Adviser is Redeye AB Telephone: +46 (0) 8 545 013 31 www.redeye.se. about IMMUNICUM AB (PUBL) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr.

Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet. Immunicum AB (publ) The event will also be available via livestream and will remain accessible in video format following E-mail: ir@immunicum.com. GlobeNewswire - 18 feb 21 kl.
Byta dator flytta filer

27 Jan 2021 Immunicum AB (publ; IMMU.ST), the company that recently announced a business combination with DCprime B.V., has signed a long-term

Immunicum AB (publ) | Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr. 556629-1786|immunicum.se . MEDIA RELATIONS Gretchen Schweitzer and Joanne Tudorica . Trophic Communications . Telephone: +49 172 861 8540 . E-mail: ir@immunicum.com. U.S. AND INTERNATIONAL INVESTO R RELATIONS Thomas Renaud .

Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com

Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer 2021-03-01 08:00 · GlobeNewswire Immunicum AB (publ) meddelar att Jeroen Rovers har utsetts till medicinsk chef Immunicum AB is a biopharmaceutical company.

2021-03-31 Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020.. Investors, media and the public are welcome to join. During the event, CEO, Sven Rohmann, COO, Sijme Zeilemaker and CSO, Alex Karlsson-Parra will present an overview of Immunicum and its development priorities. E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of … 2021-04-12 E-mail: immu@trophic.eu. About Immunicum AB (publ) Story continues. Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, 2021-04-12 1 day ago Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.